Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma
Plain-language summary
This trial is testing Benvitimod Cream for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to treatment groups, and neither patients nor doctors know which treatment is being given. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.
Who can join (key eligibility)
- Age 18 Years or older
- See full trial listing for complete eligibility
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Benvitimod Cream (DRUG): Applied topically to the randomly assigned target lesion (left or right side) once daily for up to 24 weeks. The application area will not exceed 2% of the body surface area. | Placebo cream (DRUG): A vehicle cream matching the appearance of benvitimod cream. Applied topically to the contralateral target lesion once daily for up to 24 weeks.
Benvitimod Cream, Placebo cream
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details